Literature DB >> 7727878

T-cell acute lymphoblastic leukemia with transient pure red cell aplasia associated with myasthenia gravis and invasive thymoma.

R Nishioka1, S Nakajima, Y Morimoto, H Suzuki, H Nakamura, M Suzuki.   

Abstract

A 43-year-old male developed rapidly progressing anemia and a bone marrow examination revealed pure red cell aplasia (PRCA). He was diagnosed as having myasthenia gravis (MG) and invasive thymoma, and achieved complete remission by radiation and chemotherapy six years ago. Despite increased doses of oral prednisolone from 7.5 mg/day to 60 mg/day, a diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) was made one month later based on findings of 37.2% abnormal lymphoblasts and positive surface markers for CD2, CD3 and CD7 T-cells. Cases of PRCA associated with MG and thymoma have been reported in the literature, however such a case followed by T-ALL is very rare.

Entities:  

Mesh:

Year:  1995        PMID: 7727878     DOI: 10.2169/internalmedicine.34.127

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  A population-based assessment of mortality and morbidity patterns among patients with thymoma.

Authors:  Shahinaz M Gadalla; Arun Rajan; Ruth Pfeiffer; Sigurdur Y Kristinsson; Magnus Björkholm; Ola Landgren; Giuseppe Giaccone
Journal:  Int J Cancer       Date:  2010-07-28       Impact factor: 7.396

2.  Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association.

Authors:  Yumeng Zhang; Christa Varnadoe; Ankita Tandon; Peter Forsyth; Rami Komrokji; Lubomir Sokol
Journal:  Leuk Res Rep       Date:  2020-10-06

3.  Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy.

Authors:  Masahiro Ohara; Kokoro Ozaki; Takuya Ohkubo; Akane Yamada; Yoshiyuki Numasawa; Keisuke Tanaka; Shohei Tomii; Satoru Ishibashi; Nobuo Sanjo; Takanori Yokota
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.